DSAM Partners’s Pfizer PFE Stock Holding History

DSAM Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-61,655	Closed	-$1.97M	–	59
2017 Q2	$1.97M	Buy	+61,655	New	+$1.94M	0.35%	42

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

DSAM Partners's PFE Position: Q3 2017 in Review

DSAM Partners sold out of Pfizer (PFE) in Q3 2017, closing a stake of 61,655 shares — an estimated $1.97M sold.

DSAM Partners first reported a position in PFE in Q2 2017 and held it in 1 quarter. The position peaked at $1.97M in Q2 2017. 2,042 funds tracked by Wall St. Rank hold PFE as of Q3 2017.

DSAM Partners reported no remaining Pfizer position as of Q3 2017 after selling out during the quarter.
DSAM Partners sold 61,655 Pfizer shares in Q3 2017, an estimated $1.97M.
DSAM Partners first reported a position in Pfizer in Q2 2017 and held it in 1 quarter.
DSAM Partners's Pfizer position peaked at $1.97M in Q2 2017.
2,042 funds tracked by Wall St. Rank held Pfizer as of Q3 2017.

Based on DSAM Partners's 13F filing for Q3 2017, filed 31 Oct 2017.